Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study ; volume:13 ; number:4 ; day:8 ; month:11 ; year:2010 ; pages:1-2 ; date:12.2010
Journal of the International AIDS Society / International AIDS Society ; 13, Heft 4 (8.11.2010), 1-2, 12.2010
- Urheber
-
Schneider, L.
- Beteiligte Personen und Organisationen
-
Houssaini, A.
Lambert, S.
Peytavin, G.
Agher, R.
Chermak, A.
Flandre, P.
CALVEZ, V.
Marcelin, AG
Ghosn, J.
Katlama, C.
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-13-S4-P29
- URN
-
urn:nbn:de:1111-2016052060260
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schneider, L.
- Houssaini, A.
- Lambert, S.
- Peytavin, G.
- Agher, R.
- Chermak, A.
- Flandre, P.
- CALVEZ, V.
- Marcelin, AG
- Ghosn, J.
- Katlama, C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN
Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
O424 Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients
POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
Cost-effectiveness and budget impact of lopinavir/ritonavir and atazanavir plus ritonavir regimens based on 48-week results from the CASTLE study
The Photogrammetric Week series a centennial success story
Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments
Raltegravir, etravirine and darunavir-ritonavir: a safe and successful rescue regimen in highly treatment-experienced HIV1-infected patients
Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN
Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
O424 Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients
POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
Cost-effectiveness and budget impact of lopinavir/ritonavir and atazanavir plus ritonavir regimens based on 48-week results from the CASTLE study
The Photogrammetric Week series a centennial success story
Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments
Raltegravir, etravirine and darunavir-ritonavir: a safe and successful rescue regimen in highly treatment-experienced HIV1-infected patients
Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN
Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
O424 Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients
POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
Cost-effectiveness and budget impact of lopinavir/ritonavir and atazanavir plus ritonavir regimens based on 48-week results from the CASTLE study
The Photogrammetric Week series a centennial success story
Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments
Raltegravir, etravirine and darunavir-ritonavir: a safe and successful rescue regimen in highly treatment-experienced HIV1-infected patients